ArticleJournal of nanobiotechnology2026
Biometallic peptide-drug conjugates in photo-crosslinkable hydrogels enable combined photothermal-chemotherapy against breast cancer.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stimuli-Responsive Peptides for Targeted Anticancer Drug Delivery: Current Advances and Future Outlook.Pharmaceutics · 2026Review
- Application Advances of Gold Nanoparticles in Cancer Theranostics: From Physicochemical Mechanisms to Multifunctional Nanoplatforms.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Peptide-drug conjugates (PDCs) offer a powerful therapeutic modality by integrating the targeting specificity of peptides with the cytotoxic efficacy of chemotherapeutics, thereby improving antitumor performance while reducing off-target toxicity. In this study, we engineered biometallic PDCs composed of peptide nanofibers (PNFs), gold nanoparticles (GNPs), and doxorubicin (DOX), termed PGDCs, and incorporated them into photo-responsive dual-network hyaluronic acid hydrogels for combined photothermal and chemotherapeutic (PTT/CT) treatment of breast cancer. The hydrogel was formed by mixing oxidized methacrylated hyaluronic acid (O-HAMA) with PGDCs, followed by rapid photo-crosslinking under 365 nm UV light, achieving gelation within 90 s for localized, on-demand drug deployment. The resulting O-HAMA/PGDC hydrogels exhibited pH-responsive drug release under tumor microenvironments and robust photothermal performance under NIR irradiation. In vitro and in vivo evaluations revealed strong tumor suppression, with 98% inhibition efficiency, effective tumor ablation, and minimal damage to surrounding healthy tissues. The structural modularity of PGDCs-allowing simultaneous integration of metals, peptides, and drugs-opens pathways for designing highly effective, tumor-selective nanotherapeutics with controlled activation, efficient internalization, and combined therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.